Stryker Corporation (SYK)
NYSE: SYK
· Real-Time Price · USD
391.75
5.43 (1.41%)
At close: May 15, 2025, 1:14 PM
Stryker Revenue Breakdown
| Period Ending | Dec 30, 2024 | Dec 30, 2023 | Dec 30, 2022 | Dec 30, 2021 | Dec 30, 2020 | Dec 30, 2019 | Dec 30, 2018 | Dec 30, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology Revenue | 13.52B | 11.84B | 10.61B | 9.54B | 4.96B | 5.25B | 4.99B | 4.71B | 4.42B | 4.22B | 4.15B | 4B | 3.82B | 3.71B |
| MedSurg and Neurotechnology Revenue Growth | +14.21% | +11.54% | +11.25% | +92.34% | -5.58% | +5.23% | +5.90% | +6.58% | +4.71% | +1.69% | +3.72% | +4.73% | +3.05% | n/a |
| Orthopaedics Revenue | 9.08B | 8.66B | 7.84B | 7.57B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Orthopaedics Revenue Growth | +4.79% | +10.51% | +3.54% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.3B | 2.13B | 1.9B | 1.81B | 1.84B | 1.94B | 1.7B | 1.71B | 1.78B | 1.75B | 1.46B | 1.54B | 1.71B | 1.75B | 1.6B | 1.5B | 1.57B | 1.56B | 1.24B | 1.23B | 1.33B | 1.38B | 1.29B | 1.28B | 1.4B | 1.43B | 1.24B | 1.19B | 1.24B | 1.22B | 1.1B | 1.13B | 1.1B | 1.09B | 1.06B | 1.04B | 944M | 970M | 887M | 861M | 892M |
| Selling, General, and Administrative Revenue Growth | +7.73% | +12.61% | +4.52% | -1.41% | -5.20% | +14.11% | -0.29% | -4.21% | +1.71% | +20.34% | -5.46% | -10.00% | -2.01% | +8.93% | +6.45% | -4.44% | +0.83% | +25.56% | +1.55% | -7.89% | -3.62% | +6.89% | +0.70% | -8.62% | -1.96% | +15.22% | +4.37% | -3.72% | +1.56% | +10.34% | -2.39% | +2.54% | +0.82% | +3.41% | +1.34% | +10.49% | -2.68% | +9.36% | +3.02% | -3.48% | n/a |
| Research and Development Revenue | 405M | 369M | 377M | 352M | 368M | 350M | 353M | 346M | 339M | 326M | 364M | 351M | 413M | 331M | 306M | 310M | 288M | 255M | 242M | 233M | 254M | 254M | 246M | 246M | 225M | 221M | 221M | 216M | 204M | 205M | 198M | 192M | 192M | 189M | 184M | 183M | 159M | 164M | 155M | 154M | 152M |
| Research and Development Revenue Growth | +9.76% | -2.12% | +7.10% | -4.35% | +5.14% | -0.85% | +2.02% | +2.06% | +3.99% | -10.44% | +3.70% | -15.01% | +24.77% | +8.17% | -1.29% | +7.64% | +12.94% | +5.37% | +3.86% | -8.27% | 0.00% | +3.25% | 0.00% | +9.33% | +1.81% | 0.00% | +2.31% | +5.88% | -0.49% | +3.54% | +3.12% | 0.00% | +1.59% | +2.72% | +0.55% | +15.09% | -3.05% | +5.81% | +0.65% | +1.32% | n/a |